Lacosamide
Active ingredient: Lacosamide
In short: Lacosamide oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Lacosamide oral solution is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
What is Lacosamide used for?
Lacosamide oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Lacosamide oral solution is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
Lacosamide dosage
The recommended dosage for monotherapy and adjunctive therapy for partial-onset seizures in patients 1 month of age and older and for adjunctive therapy for primary generalized tonic-clonic seizures in patients 4 years of age and older is included in Table 1. In pediatric patients, the recommended dosing regimen is dependent upon body weight. Dosage should be increased based on clinical response and tolerability, no more frequently than once per week. Titration increments should not exceed those shown in Table 1.
Table 1: Recommended Dosages for Partial-Onset Seizures (Monotherapy or Adjunctive Therapy) in Patients 1 Month and Older, and for Primary Generalized Tonic-Clonic Seizures (Adjunctive Therapy) in Patients 4 Years of Age and Older*
Age and Body Weight | Initial Dosage | Titration Regimen | Maintenance Dosage
Adults (17 years and older) | Monotherapy**: 100 mg twice daily (200 mg per day)
Adjunctive Therapy: 50 mg twice daily (100 mg per day) | Increase by 50 mg twice daily (100 mg per day) every week | Monotherapy**:
150 mg to 200 mg twice daily (300 mg to 400 mg per day)
Adjunctive Therapy:
100 mg to 200 mg twice daily (200 mg to 400 mg per day)
Pediatric patients weighing at least 50 kg | 50 mg twice daily (100 mg per day) | Increase by 50 mg twice daily (100 mg per day) every week | Monotherapy**:
150 mg to 200 mg twice daily (300 mg to 400 mg per day)
Adjunctive Therapy:
100 mg to 200 mg twice daily (200 mg to 400 mg per day)
Pediatric patients weighing 30 kg to less than 50 kg | 1 mg/kg twice daily (2 mg/kg/day) | Increase by 1 mg/kg twice daily (2 mg/kg/day) every week | 2 mg/kg to 4 mg/kg twice daily (4 mg/kg/day to 8 mg/kg/day)
Pediatric patients weighing 11 kg to less than 30 kg | 1 mg/kg twice daily (2 mg/kg/day) | Increase by 1 mg/kg twice daily (2 mg/kg/day) every week | 3 mg/kg to 6 mg/kg twice daily (6 mg/kg/day to 12 mg/kg/day)
Pediatric patients weighing 6 kg to less than 11 kg ±
Pediatric patientsweighing less than 6kg ± | Oral:
1 mg/kg twice daily(2 mg/kg/day) | Oral:
Increase by 1 mg/kg twicedaily (2 mg/kg/day) everyweek | Oral:
3.75 mg/kg to 7.5 mg/kg twice daily (7.5 mg/kg/day to 15 mg/kg/day)
*when not specified, the dosage is the same for monotherapy for partial-onset seizures and adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures. **Monotherapy for partial-onset seizures only
± indicated only for partial-onset seizures
In adjunctive clinical trials in adult patients with partial-onset seizures, a dosage higher than 200 mg twice daily (400 mg per day) was not more effective and was associated with a substantially higher rate of adverse reactions . …
How to take Lacosamide — instructions & advice from the label
Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide). The Medication Guide accompanies the product and can also be accessed on www.novadozpharma.com or by calling 1-855-668-2369.
Suicidal Thinking and Behavior
Patients, their caregivers, and families should be counseled that AEDs, including lacosamide, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers .
Dizziness and Ataxia
Patients should be counseled that lacosamide use may cause dizziness, double vision, abnormal coordination and balance, and somnolence. Patients taking lacosamide should be advised not to drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects associated with lacosamide . …
Warnings & precautions
Do not take this medicine if: None.
Antiepileptic drugs (AEDs), including lacosamide, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. …
Lacosamide side effects
The following serious adverse reactions are described below and elsewhere in the labeling:
Suicidal Behavior and Ideation
Dizziness and Ataxia
Cardiac Rhythm and Conduction Abnormalities
Syncope
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Lacosamide Tablet and Oral Solution in Adults
In the premarketing development of adjunctive therapy for partial-onset seizures, 1327 adult patients received lacosamide tablets in controlled and uncontrolled trials, of whom 1,000 were treated for longer than 6 months, and 852 for longer than 12 months. The monotherapy development program for partial-onset seizures included 425 adult patients, 310 of whom were treated for longer than 6 months, and 254 for longer than 12 months.
Partial-Onset Seizures
Monotherapy Historical-Control Trial (Study 1)
In the monotherapy trial for partial-onset seizures, 16% of patients randomized to receive lacosamide at the recommended doses of 300 and 400 mg/day discontinued from the trial as a result of an adverse reaction. The adverse reaction most commonly (≥1% on lacosamide) leading to discontinuation was dizziness. …
Drug interactions
Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients.
Lacosamide should be used with caution in patients on concomitant medications that affect cardiac conduction (sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers) including those that prolong PR interval (including sodium channel blocking AEDs), because of a risk of AV block, bradycardia, or ventricular tachyarrhythmia. In such patients, obtaining an ECG before beginning lacosamide, and after lacosamide is titrated to steady-state, is recommended. In addition, these patients should be closely monitored if they are administered lacosamide through the intravenous route .
About this medicine
The chemical name of lacosamide, the single (R)-enantiomer, is (R)-2-acetamido-N-benzyl-3-methoxypropionamide (IUPAC). Lacosamide is a functionalized amino acid. Its molecular formula is C13H18N2O3 and its molecular weight is 250.30. The chemical structure is:
Lacosamide is a white to light yellow powder. It is soluble in methanol, sparingly soluble in water and slightly soluble in acetonitrile and ethanol.
Lacosamide oral solution, USP contains 10 mg of lacosamide per mL. The inactive ingredients are acesulfame potassium, anhydrous citric acid, glycerin, methylparaben, polyethylene glycol, purified water, sodium carboxymethylcellulose, sodium chloride and sorbitol solution, strawberry flavor (including natural and artificial flavors, propylene glycol).
How it works: The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 024bca92-cac5-4832-a1ff-c1b3d5994ba0. Read the full official label on DailyMed.
Related medicines
Gabapentin Lamotrigine Pregabalin Topiramate Levetiracetam Oxcarbazepine Carbamazepine Ciclopirox